3M CO (MMM) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 0.86%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 0.86% | Share-based compensation / revenue. Period ending 2026-06-30. $217.00M ÷ $25.18B × 100 ≈ 0.86% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 25.18B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 217.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 4.62B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $25.18B | $217.00M | $4.62B | (m) | (m) | 0.86% | (m) | (m) |
| 2026-03-31 | (m) | $25.02B | $220.00M | $4.78B | (m) | (m) | 0.88% | (m) | (m) |
| 2025-12-31 | (m) | $24.95B | $225.00M | $4.63B | (m) | (m) | 0.90% | (m) | (m) |
| 2025-09-30 | (m) | $24.82B | $229.00M | $4.92B | (m) | (m) | 0.92% | (m) | (m) |
| 2025-06-30 | (m) | $24.60B | $218.00M | $4.79B | (m) | (m) | 0.89% | (m) | (m) |
| 2025-03-31 | (m) | $24.51B | $345.00M | $4.92B | (m) | (m) | 1.41% | (m) | (m) |
| 2024-12-31 | $700.00M | $24.57B | $289.00M | $4.82B | (m) | 2.85% | 1.18% | (m) | (m) |
| 2024-09-30 | (m) | $32.64B | $294.00M | $6.20B | (m) | (m) | 0.90% | (m) | (m) |
| 2024-06-30 | (m) | $32.61B | $298.00M | $1.78B | $1.34B | (m) | 0.91% | 1.33× | Reported |
| 2024-03-31 | (m) | $32.65B | $168.00M | $-8.87B | $1.20B | (m) | 0.51% | -7.37× | Reported |
| 2023-12-31 | $1.00B | $32.68B | $274.00M | $-9.13B | $942.00M | 3.06% | 0.84% | -9.69× | Reported |
| 2023-09-30 | (m) | $32.75B | $259.00M | $-9.74B | $686.00M | (m) | 0.79% | -14.20× | Reported |
| 2023-06-30 | (m) | $33.05B | $257.00M | $-2.93B | $488.00M | (m) | 0.78% | -6.00× | Reported |
| 2023-03-31 | (m) | $33.43B | $263.00M | $6.14B | $472.00M | (m) | 0.79% | 13.01× | Reported |
| 2022-12-31 | $1.10B | $34.23B | $263.00M | $6.54B | $462.00M | 3.21% | 0.77% | 14.15× | Reported |
| 2022-09-30 | (m) | $34.76B | $273.00M | $7.52B | $465.00M | (m) | 0.79% | 16.18× | Reported |
| 2022-06-30 | (m) | $35.09B | $272.00M | $5.16B | $476.00M | (m) | 0.78% | 10.83× | Reported |
| 2022-03-31 | (m) | $35.33B | $278.00M | $7.02B | $469.00M | (m) | 0.79% | 14.96× | Reported |
| 2021-12-31 | $1.24B | $35.35B | $274.00M | $7.37B | $488.00M | 3.52% | 0.77% | 15.10× | Reported |
| 2021-09-30 | (m) | $35.33B | $273.00M | $7.60B | $511.00M | (m) | 0.77% | 14.88× | Reported |
| 2021-06-30 | (m) | $34.73B | $274.00M | $7.72B | $522.00M | (m) | 0.79% | 14.80× | Reported |
| 2021-03-31 | (m) | $32.96B | $273.00M | $7.49B | $538.00M | (m) | 0.83% | 13.93× | Reported |
| 2020-12-31 | $1.15B | $32.18B | $262.00M | $7.16B | $529.00M | 3.56% | 0.81% | 13.54× | Reported |
| 2020-09-30 | (m) | $31.71B | $264.00M | $6.64B | $512.00M | (m) | 0.83% | 12.96× | Reported |
| 2020-06-30 | (m) | $31.35B | $268.00M | $6.74B | $493.00M | (m) | 0.85% | 13.67× | Reported |
| 2020-03-31 | (m) | $32.35B | $268.00M | $6.70B | $467.00M | (m) | 0.83% | 14.35× | Reported |
| 2019-12-31 | $1.25B | $32.14B | $278.00M | $6.17B | $448.00M | 3.90% | 0.87% | 13.78× | Reported |
| 2019-09-30 | (m) | $31.97B | $274.00M | $6.63B | $419.00M | (m) | 0.86% | 15.83× | Reported |
| 2019-06-30 | (m) | $32.13B | $276.00M | $6.64B | $395.00M | (m) | 0.86% | 16.80× | Reported |
| 2019-03-31 | (m) | $32.35B | $273.00M | $7.34B | $372.00M | (m) | 0.84% | 19.72× | Reported |
| 2018-12-31 | $1.25B | $32.77B | $302.00M | $7.21B | $350.00M | 3.82% | 0.92% | 20.59× | Reported |
| 2018-09-30 | (m) | $32.81B | $316.00M | $7.21B | $421.00M | (m) | 0.96% | 17.13× | Reported |
| 2018-06-30 | (m) | $32.83B | $326.00M | $7.21B | $393.00M | (m) | 0.99% | 18.33× | Reported |
| 2018-03-31 | (m) | $32.25B | $336.00M | $6.96B | $359.00M | (m) | 1.04% | 19.38× | Reported |
| 2017-12-31 | $1.33B | $31.66B | $324.00M | $7.82B | $322.00M | 4.22% | 1.02% | 24.29× | Reported |
| 2017-09-30 | (m) | $31.00B | $320.00M | $7.66B | (m) | (m) | 1.03% | (m) | (m) |
| 2017-06-30 | (m) | $30.53B | $311.00M | $7.53B | (m) | (m) | 1.02% | (m) | (m) |
| 2017-03-31 | (m) | $30.39B | $301.00M | $7.21B | (m) | (m) | 0.99% | (m) | (m) |
| 2016-12-31 | $1.23B | $30.11B | $298.00M | $7.22B | (m) | 4.07% | 0.99% | (m) | (m) |
| 2016-09-30 | (m) | $30.08B | $287.00M | $7.06B | (m) | (m) | 0.95% | (m) | (m) |
| 2016-06-30 | (m) | $30.08B | $282.00M | $7.03B | (m) | (m) | 0.94% | (m) | (m) |
| 2016-03-31 | (m) | $30.11B | $282.00M | $7.00B | (m) | (m) | 0.94% | (m) | (m) |
| 2015-12-31 | $1.22B | $30.27B | $276.00M | $6.95B | (m) | 4.04% | 0.91% | (m) | (m) |
| 2015-09-30 | (m) | $30.70B | $292.00M | $7.11B | (m) | (m) | 0.95% | (m) | (m) |
| 2015-06-30 | (m) | $31.12B | $293.00M | $7.13B | (m) | (m) | 0.94% | (m) | (m) |
| 2015-03-31 | (m) | $31.57B | $296.00M | $7.15B | (m) | (m) | 0.94% | (m) | (m) |
| 2014-12-31 | $1.19B | $31.82B | $280.00M | $7.13B | (m) | 3.75% | 0.88% | (m) | (m) |
| 2014-09-30 | (m) | $31.67B | $264.00M | $7.05B | (m) | (m) | 0.83% | (m) | (m) |
| 2014-06-30 | (m) | $31.45B | $264.00M | $6.89B | (m) | (m) | 0.84% | (m) | (m) |
| 2014-03-31 | (m) | $31.07B | $259.00M | $6.74B | (m) | (m) | 0.83% | (m) | (m) |
| 2013-12-31 | $1.15B | $30.87B | $240.00M | $6.67B | (m) | 3.73% | 0.78% | (m) | (m) |
| 2013-09-30 | (m) | $30.69B | $239.00M | $6.53B | (m) | (m) | 0.78% | (m) | (m) |
| 2013-06-30 | (m) | $30.27B | $228.00M | $6.47B | (m) | (m) | 0.75% | (m) | (m) |
| 2013-03-31 | (m) | $30.05B | $223.00M | $6.50B | (m) | (m) | 0.74% | (m) | (m) |
| 2012-12-31 | $1.08B | $29.90B | $223.00M | $6.48B | (m) | 3.61% | 0.75% | (m) | (m) |
| 2012-09-30 | (m) | $29.61B | $224.00M | $6.40B | (m) | (m) | 0.76% | (m) | (m) |
| 2012-06-30 | (m) | $29.64B | $226.00M | $6.31B | (m) | (m) | 0.76% | (m) | (m) |
| 2012-03-31 | (m) | $29.79B | $240.00M | $6.23B | (m) | (m) | 0.81% | (m) | (m) |
| 2011-12-31 | $1.04B | $29.61B | $253.00M | $6.18B | (m) | 3.50% | 0.85% | (m) | (m) |
| 2011-09-30 | (m) | $29.23B | $256.00M | $6.12B | (m) | (m) | 0.88% | (m) | (m) |
| 2011-06-30 | (m) | $28.57B | $275.00M | $6.11B | (m) | (m) | 0.96% | (m) | (m) |
| 2011-03-31 | (m) | $27.63B | $278.00M | $6.05B | (m) | (m) | 1.01% | (m) | (m) |
| 2010-12-31 | $919.00M | $26.66B | $274.00M | $5.92B | (m) | 3.45% | 1.03% | (m) | (m) |
| 2010-09-30 | (m) | $26.07B | $269.00M | $5.96B | (m) | (m) | 1.03% | (m) | (m) |
| 2010-06-30 | (m) | $25.39B | $256.00M | $5.86B | (m) | (m) | 1.01% | (m) | (m) |
| 2010-03-31 | (m) | $24.38B | $246.00M | $5.46B | (m) | (m) | 1.01% | (m) | (m) |
| 2009-12-31 | (m) | $23.12B | $217.00M | $4.81B | (m) | (m) | 0.94% | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $25.27B | $202.00M | $5.22B | (m) | (m) | 0.80% | (m) | (m) |
| 2008-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | $24.46B | $228.00M | $6.19B | (m) | (m) | 0.93% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STRYKER CORP (SYK) | United States | $103.511B | 32.39 |
| BOSTON SCIENTIFIC CORP (BSX) | United States | $64.781B | 17.29 |
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |